Rolziracetam
Rolziracetam is a nootropic drug of the racetam family.
![]() | |
![]() | |
| Clinical data | |
|---|---|
| Other names | 2,6,7,8-tetrahydro-1H-pyrrolizine-3,5-dione |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C7H9N2O2 |
| Molar mass | 139.152 g/mol g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| | |
Rolziracetam was found to improve performance on a delayed-response task in aged rhesus monkeys. It has a wide margin of safety in animals and has been evaluated for use in cognitively impaired human subjects. [1]
See also
References
- Butler DE, Leonard JD, Caprathe BW, L'Italien YJ, Pavia MR, Hershenson FM, Poschel PH, Marriott JG. Amnesia-reversal activity of a series of cyclic imides. Journal of Medicinal Chemistry. 1987 Mar;30(3):498-503.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.

